Login
Companies $IRD
$4.10 +$0.06 (1.49%) After hours
Opus Genetics, Inc. logo

Opus Genetics, Inc.

opusgtx.com

What Do They Do?

Develops gene therapies for inherited retinal diseases and eye-drop treatments for other eye disorders, for people with vision conditions.

How Do They Make Money?

Viatris reimburses Opus for research and development work; Opus can also receive upfront fees when a license is transferred, milestone payments when milestones are reached, and royalties when partner product sales occur.

FY2025 revenue

Who Are Their Customers?

Viatris is a commercialization partner for phentolamine; it reimburses Opus for development work and handles commercialization for approved indications.

Do Revenues Turn Into Profits?

No. It lost $49.6M in FY2025.

Operating income, FY2025
−272% of revenue
▲ +38% (Loss) vs FY2024 (−$62.1M, −565%)
Net income, FY2025
−349% of revenue
▲ +14% (Loss) vs FY2024 (−$57.5M, −523%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −63%
vs $3.1M in Q3 FY2025
Net income
▼ −166% (Loss)
vs −$17.5M in Q3 FY2025
  • Nov 10, 2026 FDA approves phentolamine for presbyopia The approval triggers a milestone payment to Opus from commercialization partner Viatris.

Growing. Revenue grew 24.1x in 4 years, from $589K in FY2021 to $14.2M in FY2025, about 122% a year.

Shift toward gene therapies Earlier, the business centered on small-molecule candidates; the latest report centers on gene therapies for inherited retinal diseases while retaining phentolamine eye drops.

Who Do They Compete With?

Competes with MeiraGTX, Octant Bio, Lenz Therapeutics, AbbVie, TenPoint Therapeutics, and Sandoz

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support